Results 121 to 130 of about 68,288 (264)

Clinical and Genetic Landscape of Glioblastoma, IDH‐Wildtype With FGFR Gene Family Alterations

Cancer Science, EarlyView.
We analyzed 1076 cases of glioblastoma, IDH‐wildtype (GBM, IDH‐wt) using the C‐CAT genomic database to clarify the clinical and genetic features of FGFR alterations. FGFR::TACC fusions and FGFR1 mutations were identified in distinct subsets and were associated with unique co‐mutation patterns.
Yasuhito Kegoya, Yoshihiro Otani, Ryo Mizuta, Ryosuke Ikemachi, Mako Kamiura, Joji Ishida, Shinichi Toyooka, Daisuke Ennishi, Shuta Tomida, Shota Tanaka   +9 more
wiley   +1 more source

Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression

Clinical Cancer Research, 2019
Purpose: Previous sequencing studies revealed that alterations of genes associated with DNA damage response (DDR) are enriched in men with metastatic castration-resistant prostate cancer (mCRPC). BRCA2, a DDR and cancer susceptibility gene, is frequently
G. Chakraborty, J. Armenia, Ying Z. Mazzu, S. Nandakumar, Konrad H. Stopsack, M. Atiq, K. Komura, Lina Jehane, Rahim Hirani, Kalyani Chadalavada, Yuki Yoshikawa, Nabeela Khan, Yu Chen, W. Abida, L. Mucci, G. Lee, G. Nanjangud, P. Kantoff   +17 more
semanticscholar   +1 more source

Early but Quality Diagnosis: On Breast Cancer and Its Risk Factors [Letter]

Breast Cancer: Targets and Therapy, 2023
Syeda Sakina Zehra, Zoha Turabee, Mohadisa Asif Rawalia Karachi Medical and Dental College, Karachi, PakistanCorrespondence: Syeda Sakina Zehra, Tel +92 3322609216, Email szehra362@gmail ...
Zehra SS, Turabee Z, Rawalia MA
doaj  

FOLFIRINOX vs. Gemcitabine/Nab‐Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C‐CAT Database Study

Cancer Science, EarlyView.
In a large real‐world C‐CAT cohort of unresectable or recurrent pancreatic cancer, we evaluated outcomes with first‐line FOLFIRINOX versus gemcitabine/nab‐paclitaxel by BRCA2 pathogenic variant and TMB status. Survival was more strongly associated with therapeutic sequencing than the initial regimen, supporting early molecular profiling to optimize the
Kazuyuki Mizuno, Takuya Ishikawa, Takanori Ito, Yuko Takano, Osamu Maeda, Hiroki Kawashima, Yuichi Ando   +6 more
wiley   +1 more source

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers

Nature Communications, 2017
Complete loss of BRCA1 or BRCA2 function is associated with sensitivity to DNA damaging agents. However, not all BRCA1 and BRCA2 germline mutation-associated tumors respond.
K. Maxwell, B. Wubbenhorst, Brandon M. Wenz, Daniel De Sloover, J. Pluta, Lyndsey Emery, A. Barrett, A. Kraya, Ioannis Anastopoulos, Shun Yu, Yuchao Jiang, Hao Chen, Nancy R. Zhang, Nicole M. Hackman, K. D’Andrea, R. Daber, J. Morrissette, N. Mitra, M. Feldman, S. Domchek, K. Nathanson   +20 more
semanticscholar   +1 more source

Early‐Onset Digestive System Cancers: Risk Factors and Clinicopathological and Molecular Features Across Organ Sites

Cancer Science, EarlyView.
Shared risk factors, clinical features, and tumor characteristics across multiple early‐onset cancer types are shown in this Graphical Abstract. Integrative approaches combining molecular pathology, oncology, and population sciences offer opportunities to clarify underlying mechanisms and help us develop preventive strategies for early‐onset cancers ...
Nobuhiro Nakazawa, Satoko Ugai, Atsushi Kondo, Kosuke Matsuda, Shu Kato, Genki Usui, Shiori Tanaka, Hwa‐Young Lee, Xinyuan Zhang, Hideo Miyagawa, Mai Chan Lau, Hiroshi Saeki, Yukihide Kanemitsu, Andrew T. Chan, Shuji Ogino, Minkyo Song, Juha P. Väyrynen, Tomotaka Ugai   +17 more
wiley   +1 more source

Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

Journal of the National Cancer Institute, 2017
Background: Genome-wide association studies (GWAS) have identified 94 common single-nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk and 18 associated with ovarian cancer (OC) risk. Several of these are also associated with risk of
Karoline B. Kuchenbaecker, L. McGuffog, Daniel Barrowdale, Andrew Lee, P. Soucy, S. Healey, J. Dennis, M. Lush, M. Robson, A. Spurdle, S. Ramus, N. Mavaddat, M. Terry, S. Neuhausen, U. Hamann, M. Southey, E. John, W. Chung, M. Daly, S. Buys, D. Goldgar, C. M. Dorfling, E. J. van Rensburg, Y. Ding, B. Ejlertsen, A. Gerdes, T. V. Hansen, S. Slager, Emily J. Hallberg, J. Benítez, A. Osorio, N. Cohen, W. Lawler, J. Weitzel, P. Peterlongo, V. Pensotti, R. Dolcetti, M. Barile, B. Bonanni, J. Azzollini, S. Manoukian, B. Peissel, P. Radice, A. Savarese, L. Papi, G. Giannini, F. Fostira, I. Konstantopoulou, J. Adlard, C. Brewer, J. Cook, R. Davidson, D. Eccles, R. Eeles, Steve Ellis, D. Frost, S. Hodgson, L. Izatt, F. Lalloo, K. Ong, A. Godwin, N. Arnold, B. Dworniczak, C. Engel, A. Gehrig, E. Hahnen, J. Hauke, K. Kast, A. Meindl, D. Niederacher, R. Schmutzler, R. Varon‐Mateeva, S. Wang-gohrke, B. Wappenschmidt, L. Barjhoux, M. Collonge-Rame, Camille Elan, L. Golmard, E. Barouk-Simonet, F. Lesueur, S. Mazoyer, Johanna Sokolowska, D. Stoppa-Lyonnet, C. Isaacs, K. Claes, B. Poppe, M. de la Hoya, V. García-Barberán, K. Aittomäki, H. Nevanlinna, M. Ausems, J. D. de Lange, E. G. Gómez Garcia, F. Hogervorst, C. Kets, H. Meijers-Heijboer, J. Oosterwijk, M. Rookus, C. V. van Asperen, A. V. D. van den Ouweland, H. V. van Doorn, T. V. van Os, A. Kwong, E. Oláh, O. Díez, J. Brunet, C. Lázaro, A. Teule, J. Gronwald, A. Jakubowska, Katarzyna Kaczmarek, J. Lubiński, G. Sukiennicki, R. Barkardottir, J. Chiquette, S. Agata, M. Montagna, M. Teixeira, Sue-Kyung Park, Curtis L. Olswold, M. Tischkowitz, L. Foretova, Pragna Gaddam, J. Vijai, G. Pfeiler, C. Rappaport-Fuerhauser, C. Singer, M. Tea, M. Greene, J. Loud, G. Rennert, E. Imyanitov, P. Hulick, J. Hays, M. Piedmonte, G. Rodriguez, J. Martyn, G. Glendon, A. Mulligan, I. Andrulis, A. Toland, U. Jensen, T. Kruse, I. Pedersen, M. Thomassen, M. Caligo, S. Teo, R. Berger, E. Friedman, Y. Laitman, B. Arver, Å. Borg, H. Ehrencrona, Johanna Rantala, O. Olopade, P. Ganz, R. Nussbaum, A. Bradbury, S. Domchek, K. Nathanson, B. Arun, P. James, B. Karlan, J. Lester, J. Simard, P. Pharoah, K. Offit, F. Couch, G. Chenevix-Trench, D. Easton, A. Antoniou   +170 more
semanticscholar   +1 more source

Quality of Life After Bilateral Risk-Reducing Mastectomy and Simultaneous Reconstruction Using Pre-Pectoral Silicone Implants

Patient Preference and Adherence, 2021
Nick Spindler,1 Franziska Ebel,1 Susanne Briest,2 Sandra Wallochny,2 Stefan Langer1 1Department of Orthopedic Surgery, Traumatology and Plastic Surgery, University Hospital Leipzig, Leipzig, Germany; 2Department of Gynecology, Women’s and Children ...
Spindler N, Ebel F, Briest S, Wallochny S, Langer S   +4 more
doaj  

Genomic Profiling in Localized Prostate Cancer: Associations With Biochemical Recurrence and Response to Salvage Radiotherapy

Cancer Science, EarlyView.
Early screening for somatic alterations in localized prostate cancer could help predict biochemical recurrence risk and optimize salvage therapy selection. ABSTRACT The clinical significance of comprehensive genomic profiling (CGP) has been established in metastatic castration‐resistant prostate cancer (PC).
Kenji Zennami, Tetsuya Takimoto, Takuhisa Nukaya, Makoto Sumitomo, Mayu Takeda, Eiji Sugihara, Hideyuki Saya, Ryoichi Shiroki   +7 more
wiley   +1 more source

Molecular pathology of phyllodes tumours of the breast—much more than MED12

Histopathology, EarlyView.
Phyllodes tumours can develop from fibroadenomas bearing MED12 variants by the development of pTERT alterations (“MED12 pathway”) or de novo (“MED12 independent pathway”). Grade progression is associated with increasing genetic complexity including cancer driver gene aberrations. Molecular alterations can be useful in assigning grade and distinguishing
Jia‐Min B Pang, Kylie L Gorringe, Puay Hoon Tan, Stephen B Fox   +3 more
wiley   +1 more source